Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Inyección epidural de filtrado de líquido amniótico estéril.

1 de septiembre de 2026 actualizado por: Zack McCormick, University of Utah

Un estudio prospectivo aleatorizado doble ciego de fase I/II de la inyección epidural de filtrado de líquido amniótico estéril para el tratamiento del dolor radicular lumbosacro debido a la estenosis espinal: el ensayo SAFE (Mejora de la seguridad y los resultados en el tratamiento del dolor y la discapacidad relacionada con la estenosis espinal) .

There is a large population of patients with lumbosacral radicular pain due to spinal stenosis who do not respond to physical therapy or oral medication management, yet wish to avoid spinal surgery or are simply not candidates due to medical co-morbidity. Given the natural history of lumbar spinal stenosis, these patients typically suffer from chronic pain and disability. Currently, the typical treatment for this population is serial corticosteroid injection. The efficacy of the treatment specifically for the indication of spinal stenosis is in question and is associated with both concerning chronic sequelae and the risk, although low, of catastrophic neurologic compromise. Alternatively, hAF is a promising new biologic treatment with neuro-protective and regenerative properties. Early studies demonstrate its anti-inflammatory properties, with high levels of anti-inflammatory cytokines, in addition to its ability to assist with regeneration of peripheral nerves. Furthermore, it has a favorable side-effect profile without concern for long-term sequelae or potential for neurologic compromise. The present study aims to determine if epidural injection of hAF compared to the corticosteroid dexamethasone is more effective for the treatment of lumbosacral radicular pain due to spinal stenosis, as measured by pain, disability, psychological function, oral analgesic use, and avoidance of surgery. Evidence for superiority of epidural hAF compared to dexamethasone injection would change the treatment paradigm for refractory radicular pain due to spinal stenosis. Furthermore, even if shown to be non-inferior to epidural dexamethasone, epidural hAF would be favored given its superior safety profile. Thus, this research has the potential to improve outcomes and patient safety in a very large population with chronic pain.

Descripción general del estudio

Descripción detallada

Lumbar spinal stenosis is a common cause of chronic pain and disability in older adults and is the leading reason for spinal surgery in older adults. In this condition, degenerative changes in intervertebral discs and osseous anatomy of the spine result in narrowing of the spinal canal and neuroforamen in close proximity to the traversing spinal nerve roots, causing back and radicular leg pain, paresthesias and weakness. In the absence of a progressive neurologic deficit, initial treatment of lumbosacral radicular pain includes physical therapy, activity modification, and oral neuropathic or analgesic medications. If this conservative approach fails to relieve pain, an image guided epidural steroid injection (ESI) is the second-line treatment. Surgical decompression may be a treatment option for some patients who fail conservative therapy, but it is not uniformly effective and is associated with substantial direct and indirect risks. Further, some patients are unwilling to undergo invasive surgical treatments, and in others, surgery is contraindicated due to medical co-morbidities.

Epidural steroid injections are widely used for the treatment of spinal stenosis. Over 25% of all epidural steroid injection in the Medicare population are administered for the treatment of pain associated with spinal stenosis, accounting for more than 500,000 injections per year. When performed with sterile technique and fluoroscopic-guidance, epidural spine injections of steroid are safe. However, steroid use in the epidural space is associated with rare but catastrophic sequelae including paraplegia due to spinal cord infarction. The larger size or aggregation of particulate steroids likely obstructs arteriolar blood flow to the spinal cord if inadvertently injected into radicular arteries during TFESI. In addition, epidural steroid use is associated with common immediate/short-term adverse events such as facial flushing, headache, insomnia, transient hypertension, increased blood glucose in patients with diabetes. Injections must often be repeated when administered for chronic radicular pain given a typical natural history of life-long pain associated with this condition, which increases the risk of long-term sequelae including osteoporosis, adrenal suppression, hypertension, cataracts, gastrointestinal bleeding, and immune system dysfunction among many others.

Furthermore, the injection treatment paradigm for patients with spinal stenosis has not been optimized. While transforaminal epidural steroid injection appears to be superior to both placebo saline injection and lidocaine injection at short-term to intermediate follow-up when performed for the indication of radicular pain due to acute disc herniation, the highest quality evidence to date suggests a lesser degree of efficacy for the indication of leg pain due to spinal stenosis This is particularly problematic given that radicular pain related to disc herniation is self-limited, whereas spinal-stenosis related radicular pain does not tend to improve over time. Thus, there is a large group of patients with spinal stenosis who fail to respond to physical therapy and oral medication management, yet either wish to avoid spinal surgery or are not eligible, and suffer from chronic pain and debility given the poor treatment options. Clearly, better treatments with more optimal safety and side-effect profiles compared to epidural corticosteroids must be investigated in this context.

There is therefore a critical need to identify safe and effective treatments for this common clinical condition, which would allow for improved patient function and pain relief. Amniotic Fluid (AF) is a promising new biologic treatment with neuro-protective and regenerative properties. Early after conception and until the mother's water breaks for the delivery of their infant, the fetus is bathed in amniotic fluid. AF functions as a supportive cushion to the fetus and provides a protective environment. AF is a rich source of nutrients, cytokines and growth factors that are required for fetal development and maturation. AF also contains multiple cell types with the potential to differentiate along multiple cell lineages. The protective and regenerative properties of AF are achieved via the exchange of water and solutes with surrounding tissues. This is accomplished via the utilization of different pathways during the course of a pregnancy that likely contribute to changes in the composition of AF with gestational age.

Early evidence demonstrates that concentrates of AF inhibit the development of peritonitis and accelerate defense-repair mechanisms within damaged joints, demonstrating protective biological properties. Since these early publications, more sophisticated evaluations have revealed the presence of antimicrobial, immunomodulatory, and growth-promoting activities of AF. For example, low AF antimicrobial activity is associated with a high incidence of an infectious syndromes in pregnant women. Components with antimicrobial, antiviral and antifungal activity that are present in AF include lysozyme, peroxidase, transferrin, beta-lysin, immunoglobulins and zinc-peptide complexes. Immunomodulatory properties of AF are evident from studies showing that enteral feeding of AF suppresses the pro-inflammatory responses in preterm pigs with necrotizing enterocolitis. Further, growth-promoting activities of AF are supported by both animal studies and in vitro studies, showing that AF can enhance neochondrogenesis, regenerate peripheral nerves and bone, accelerate re-epithelialization in corneas, and promote healing of human skin wounds. Some of the factors that are found in AF that may contribute to these activities include inflammatory mediators such as TNF-a, IL-6, IL8, and IL-1048 trophic factors that include EGF, IGF-1, FGF, HGF and TGF-a, and hyaluronic acid, an important factor in promoting re- epithelialization in human skin wounds.

Human AF also contains factors that appear to minimize scarring and adhesions. Ozgenel et al, describe how adhesions and scarring are reduced or eliminated in a peripheral nerve rat model. It is interesting that a fetal incision made early in gestation will heal without a scar whereas one made in late gestation heals with scar formation. Hyaluronic acid, which is found in high levels in AF, inhibits collagen synthesis. This hyaluronic acid-rich environment is due to a relative lack of hyaluronidase in AF and to the presence of hyaluronic acid-stimulating factor in AF. In a study investigating the effect of AF on proteases important to wound healing, human AF was shown to enhance collagenase activity, but to inhibit activities of hyaluronidase, elastase, and cathepsin.

Tipo de estudio

Intervencionista

Inscripción (Actual)

58

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • University of Utah Orthopaedic Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patients who are ≥ 18 years old
  2. Pain in the low back and lower extremity (pain NRS >4) with buttock/leg pain > back pain.
  3. Radicular distribution of leg pain based on history and correlation with advancing imaging. Radicular pain may be fixed or claudicatory in nature.
  4. Pain resistant to a trial of conservative therapy (i.e. oral steroids, NSAIDs, opioids, muscle relaxants, physical therapy, chiropractic or other non-invasive care) for at least 3 months.
  5. Mild-moderate-severe lumbar foraminal or subarticular zone stenosis, and/or mild-moderate central canal spinal stenosis identified by MRI or CT scan according to radiologic criteria (Boden 1996).
  6. Ability to read English and complete the assessment questionnaires.
  7. Must have been 90 days since last steroid injection.

Exclusion Criteria:

  1. Patients in the opinion of the treating investigator who are unwilling or unable to comply with study procedures.
  2. Systemic infection or local infection over planned injection site.
  3. Bleeding disorder, current use of anticoagulants or anti-platelet medications.
  4. Intrinsic spinal cord lesions.
  5. History of central neurologic, cerebrovascular, demyelinating or muscular disease.
  6. Severe vascular, pulmonary or coronary artery disease that limits ambulation including recent myocardial infarction (within the last 6 months).
  7. Allergy to medications being used for injection procedures.
  8. Women who are pregnant, breastfeeding, or plan to become pregnant while participating in the study. If of child-bearing potential, unwillingness to use effective birth control while participating in the study.
  9. Cognitive deficit or motor neuron disease.
  10. Spinal instability requiring surgery.
  11. History of spinal fusion surgery
  12. Metastatic cancer.
  13. Concordant pain with internal rotation of the hip (or known hip joint pathology)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Transforaminal epidural Amniotic Fluid injection

Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7") will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 3 mL of Amniotic Fluid will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups.

Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach

Otros nombres:
  • Sterile Amniotic Fluid Filtrate
Comparador activo: Transforaminal epidural dexamethasone injection

Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7") will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups.

Dexamethasone sodium phosphate mixed with 2 mL sterile water will be injected by transforaminal approach

Otros nombres:
  • Dexametasona

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The Percentage of Participants Reporting >50% Improvement in the Numeric Rating Scale Pain Score at 3 Months; Back and Leg Pain Separately.
Periodo de tiempo: 3 months

Categorical measures of both pain and function will be used for the primary outcome analysis given recent recommendations by the National Institute of Health.

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean Change in the Numeric Pain Rating Scale (NPRS) Pain Score (Back and Leg Pain Separately).
Periodo de tiempo: From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

NPRS scale from 0 to 10, with 0 being no pain and 10 being worst imaginable pain

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
The Number of Participants Reporting >30% Improvement in the Oswestry Disability Index at 3 Months
Periodo de tiempo: 3 months

How many participants reported a greater than 30% improvement in the Oswestry Disability Index at 3 months.

3 months
Mean Change in Oswestry Disability Index (ODI) Score Improvement
Periodo de tiempo: From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

The Oswestry Disability Index (ODI) consists of 10 questions, scored from 0-5 (minimum to maximum).

The point total from each section is summed, divided by the total points possible of all sections answered, and multiplied by 100 to create a percentage disability from 0-100%, with a lower percentage indicating less disability.

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
The Percentage of Participants Reporting >30% Improvement in the Swiss Spinal Stenosis Questionnaire (SSSQ) Score.
Periodo de tiempo: From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

The Swiss Spinal Stenosis Questionnaire (SSSQ) used for this study is scored by summing responses across two subscales:

Symptom severity:

Questions 1-4: Assess pain in the back and lower limbs. Questions 5-7: Assess neuroischemic symptoms (numbness, weakness, balance).

Scoring:

Each question (except Q7) is scored on a 1 to 5 scale, with 1 indicating no symptoms and 5 indicating very severe symptoms.

Question 7 (balance) has three options: 1, 3, or 5. 7 Calculation: Sum the scores for questions 1-7 to get the total symptom severity score.

Physical function:

Questions 8-12: Assess walking capacity and functional limitations. Scoring: Each question is scored on a 1 to 4 scale, with higher scores indicating greater disability.

Calculation: Sum the scores for questions 8-12 to get the total functional disability score.

The scores from follow-up visits will be compared to the participant's Baseline scores to calculate improvement percentage.

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
Mean Change in the Swiss Spinal Stenosis Questionnaire (SSSQ) Score
Periodo de tiempo: From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

Swiss Spinal Stenosis Questionnaire (SSSQ) is scored across two scales: Symptom Severity (7 Q) and Physical Function (5 Q). The Symptom Severity scale is subdivided into two domains: Pain and Neuroischemic Symptoms.

  1. Symptom Severity Scale (Q 1-7) This section evaluates pain intensity and frequency (Pain domain; Q 1-4), as well as neuroischemic symptoms such as numbness, tingling, and weakness (Neuroischemic Symptoms domain; Q 5-7).

    • Scoring Range: 1 - 5 per question, (1 = none, 5 = very severe) Highest Pain score=20 Lowest=4 / Highest Neuro=15 Lowest=3
    • Calculation: Average of answers.
    • Interpretation: A higher score indicates a greater severity of symptoms.
  2. Physical Function Scale (Q 8-12) This section measures how much symptoms restrict daily activities

    • Scoring Range: 1 - 4 per question (1 = normal activity, 4 = severe limitation) Highest score=20 / Lowest=5
    • Calculation: Average of answers
    • Interpretation: Higher score shows greater functional disability.
From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Zachary L McCormick, MD, University of Utah

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de junio de 2021

Finalización primaria (Actual)

1 de julio de 2025

Finalización del estudio (Actual)

1 de julio de 2025

Fechas de registro del estudio

Enviado por primera vez

28 de agosto de 2020

Primero enviado que cumplió con los criterios de control de calidad

28 de agosto de 2020

Publicado por primera vez (Actual)

3 de septiembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de septiembre de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir